FDA approves Syndax’s menin inhibitor with black-box warning; GSK’s ADC deal

Plus, news about Regeneron, Innovent, Xencor, MapLight Therapeutics, Genmab, Pfizer, Merck and Ferring Pharmaceuticals: ⬛ Syndax’s Revuforj is approved in another indication: The menin inhibitor can now be used to treat ...